Registration successful.
Account activated – Pending validation
Your account has been activated successfully, but we still need to validate you as a UK healthcare professional. We’ll send you an email with the result. Please note this could take up to 10 days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website.
Explore Omjjara's Events and Webinars
OMJJARA▶︎ (momelotinib)
See your eligible adult patients who have myelofibrosis (MF) with moderate to severe anaemia through a different lens.
Omjjara is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anaemia who have primary myelofibrosis (MF), post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis and who are Janus Kinase (JAK) inhibitor naïve or have been treated with ruxolitinib.1
Be the first to know about upcoming webinars, access helpful resources for your patients and stay up to date with the latest updates shaping the field.
Omjjara Mode of Action Video
▶︎ This medicine is subject to additional monitoring. This will allow quick identification of new safety information.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store.
Adverse events should also be reported to GlaxoSmithKline on 0800 221 441 or UKSafety@gsk.com
Reference:
- OMJJARA UK SmPC https://www.medicines.org.uk/emc/product/15492/smpc
May 2026 | PM-GB-MML-WCNT-250007 (V1.0)
